Single Photon Emission Computed Tomography/Computed Tomography With Pentavalent 99mTc Dimercaptosuccinic Acid in Patients With Brain Glioma; Correlation With IDH Mutation
1 other identifier
observational
40
0 countries
N/A
Brief Summary
The aim of this study is to evaluate the correlation between degree of 99mTc-DMSA (V) uptake at SPECT/CT and IDH mutation in patients with brain glioma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2022
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2022
CompletedFirst Submitted
Initial submission to the registry
October 20, 2022
CompletedFirst Posted
Study publicly available on registry
October 25, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2023
CompletedOctober 25, 2022
October 1, 2022
1 year
October 20, 2022
October 23, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
degree of 99mTc-DMSA (V) uptake at SPECT/CT
measured by calculating quantitative index of 99mTc-DMSA (V) uptake at SPECT/CT as a biomarker for IDH mutation expression
Baseline
Secondary Outcomes (1)
IDH mutation
Baseline
Interventions
A dose of 555-740 MBq 99mTc (V) DMSA is injected into a peripheral vein. Delayed brain SPECT/CT images will be obtained at 2-3 h after injection. Imaging will be performed on a hybrid dual head SPECT/CT machine (Symbia T, Siemens, Erlangen, Germany) fitted with a low energy high-resolution collimator, using 15% energy window set at 140 keV. SPECT images are acquired in a noncircular 360° arc for a total of 64 frames, 25-s/frame, using a 128 × 128 matrix size. Following SPECT acquisition, low-dose CT is acquired for anatomical localization and attenuation correction. The used CT parameters are: tube voltage 130 kV, tube current 80 mA, and slice thickness 1 mm. Images will be reconstructed using manufacturer's iterative protocol (four iterations, four subsets, and Gaussian filter 8 mm). The reconstructed images will be reviewed on a viewing workstation running OsiriX MD version 6.5.2 (Pixmeo, Bernex, Switzerland).
Eligibility Criteria
Patients with Brain Glioma and satisfy the inclusion criteria visiting the nuclear medicine unit at Assiut university hospital
You may qualify if:
- Patients with a pathologically proven glioma. • patients conscious to provide informed consent
You may not qualify if:
- Pregnant women.
- severely ill patients and those with disturbed conscious level,
- patients who were judged that they cannot lie down comfortably without movement for at least 20 min
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Links
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant lecturer
Study Record Dates
First Submitted
October 20, 2022
First Posted
October 25, 2022
Study Start
October 1, 2022
Primary Completion
October 1, 2023
Study Completion
November 1, 2023
Last Updated
October 25, 2022
Record last verified: 2022-10